VitaSTEM — The first AI-enabled longevity project and inaugural IP-Token launched by Aubrai, VitaDAO’s decentralized scientific agent. After six months of deep research on public and proprietary single-cell RNA-seq and multi-omics datasets, our scientific research team analyzed more than 850,000 human hematopoietic stem cell transcriptomes from donors aged 23–91 (both male and female). This effort uncovered 100+ high-potential rejuvenation target genes and revealed critical drivers of decline such as RhoA hyperactivation, CD38 upregulation, and CCR9 downregulation. Rather than treating HSC aging as a single defect, Aubrai recognized it as convergent damage across interconnected systems, generating a comprehensive multi-modal, five-phase rejuvenation protocol targeting transcriptional stress, metabolic dysfunction, and epigenetic drift in parallel. The agent shortlisted target genes using insights from thousands of peer-reviewed publications and private data and also optimized experimental protocols to guide in vitro and upcoming pre-clinical testing. For the first time, human researchers and AI Agents collaborate as co-scientists in the creation of pioneering scientific IP.

D1ckGPT is a BioAgent that makes your D1ck stronger by assessing its age and guiding you on how to reverse it. Trained on 600+ clinician-curated studies with its own Decentralized Knowledge Graph, every interaction enhances D1ckGPT's intelligence, revolutionizing traditional care and accelerating science and drug discovery in men's health. Whether it’s optimizing testosterone, boosting cognitive edge, or getting smarter about longevity.

Galectin-3 Inhibitors project tests a small molecule, previously used in peripheral indications, for treating neuroinflammation in an Alzheimer’s mouse model. By blocking Galectin-3, it aims to reduce brain inflammation, with potential in other neurodegenerative diseases. The Galectin-3 Inhibitors project is testing the concept of treating neuroinflammation through a small molecule known to inhibit Galectin-3 in peripheral indications, via direct injection to the brain in the mouse model of Alzheimer’s disease. Galectin-3 is involved in neuroinflammation, thereby the project has a potential to be used in multiple neurodegenerative diseases. Galectin-3 inhibitors are a new class of drugs that could effectively treat neuroinflammation. Galectin-3 has shown to be a critical element in both peripheral as well as neuroinflammation. The project advances how inhibition leads to a resolution of brain inflammation.

Nootropics DAO is building the world's most effective global infrastructure for decentralized research, discovery, and commercialization of powerful solutions for human cognitive enhancement. By creating an open-science ecosystem that aligns professional researchers, citizen-scientists, and biohackers to govern a community-directed research and development pipeline with hyper-efficient feedback loops, Nootropics DAO is operating to become the dominant force in the rapidly growing nootropics industry.

Can we add years to dogs' lives, and life to their years? Dog Years will lead decentralized clinical trials in pursuit of extending canine healthspan, creating a future where dogs and their humans share longer, healthier lives together.

DALYA applies cutting edge methods of drug development to diseases neglected by the pharma industry (i.e. diseases that primarily impact low-income countries) – to serve the billions of people whose health needs are not being met by current drug R&D institutions.

FatDAO addresses the global obesity crisis, aiming to advance research and solutions for weight management and metabolic health. With 2.2 billion overweight or obese adults worldwide, obesity and related diseases like diabetes and cardiovascular conditions severely impact public health and quality of life. Our vision is to become the “on-chain Eli Lilly,” driving breakthroughs in obesity treatment and reshaping the future of metabolic health.

With 39 million AMR deaths projected by 2050, MicroDAO unites community governance with sustainable innovation to fund tools, data & AMR solutions. Our marketplace drives core revenue, while the MICRO token empowers contributors, fuels the treasury & ensures impact.

BiomeAI is a cutting-edge health assistant powered by over 1,000 rigorously curated scientific studies on microbiome science and real-world experiments, designed to help people make smarter, personalized health choices with trustworthy data as its foundation. Built and advised by a team of top experts in gut health and AI, BiomeAI blends deep scientific credibility with participatory governance model to let users test, learn, and figure out what works for them. Every experiment and health insight feeds into a transparent, collective knowledge base that grows with you and the active community. Holding $BIOMEAI grants exclusive first access to the most validated N=10 trial protocols and the next big gut health breakthrough. Top yappers and traders gain a winning chance to earn free microbiome tests by completing community missions, turning engagement into tangible health value.

Aubrai is the world’s first decentralized scientific agent with knowledge stemming from thousands of private lab notes, internal chats and unpublished insights from the lab of Dr. Aubrey de Grey and the collective intelligence of the global longevity community. Co-developed by VitaDAO and BIO, the first BioAgent is designed to fight the greatest killer of all time: Aging. As an onchain AI co-scientist, Aubrai can generate and validate hypotheses, design wet-lab experiments and encrypt data when asked, enriching research outputs while protecting trade secrets. At the heart of Aubrai's mission lies the Robust Mouse Rejuvenation (RMR2) project – Aubrey's ambitious study to double the remaining lifespan of middle‑aged mice. If successful, it could be aging's "AlphaFold moment": a proof that multi‑target rejuvenation works and is worth scaling.

eDMT Commons enables shared governance over multiple R&D efforts into how the brain regulates its own DMT. This Commons IPT coordinates funding across diverse approaches, accelerating discovery while ensuring knowledge remains community-governed. Token holders benefit from any project funded by or joining the consortium. The flagship project seeks to uncover how endogenous DMT is regulated in the mammalian brain by isolating and sequencing enzymes that act as an “off switch” for DMT production. This work could provide the foundation for protocols to induce sustained DMT states through internal pathways (“endo-DMTx”), opening new therapeutic avenues for neuroprotection, learning, and mood regulation.

Revolutionizing spine care for millions worldwide. By leveraging blockchain, AI, and collaborative decentralized science, SpineDAO creates an open platform for optimizing surgical decisions, improving patient outcomes, and democratizing access to spine knowledge.

Curing the 10,000 rare genetic diseases. We are uniting patient groups and populations to tackle the $1T rare disease market. We're going directly to patients, turning them into research scientists, and making them the center of focus.

The Quantum Biology DAO accelerates the quantum biology field through community building, open governance, scientific experimentation, research grants, and IP development. Together we will understand and manipulate biology at the quantum level.